Hemoglobin Oxygen Therapeutics LLC

Red blood cell substitutes

February 16, 2018

Nina Notman reports on progress towards products that can, when necessary, replace donor red blood cells

More news
April 18, 2019
Hemopure Plays A Pivotal Role in A Pioneering Study Published in Nature

Researchers from Yale School of Medicine Demonstrated Restored Cellular Functions In Pig Brains After Death Using Hemopure. Hemopure May Become a Novel, Broadly Applicable and Easy-to-Handle Perfusion Solution For Multiple Organs. SOUDERTON, Pa., April 18, 2019 /PRNewswire/ — Hemoglobin Oxygen Therapeutics LLC (HbO2 Therapeutics), a world leader in oxygen-carrying solutions, today announces pioneering research conducted…

April 9, 2019
Hemoglobin Oxygen Therapeutics LLC Announces Preclinical Results on Hemopure in Kidneys Discarded for Human Transplantation

Massachusetts General Hospital Study Suggest that Hemopure is an Acceptable Alternative for Human Blood Products in Kidneys Undergoing Machine Perfusion Technology. Study Published in The American Journal of Transplantation. SOUDERTON, PA, April 9, 2019 /PRNewswire/ — Hemoglobin Oxygen Therapeutics LLC ( HbO2Therapeutics), a biopharmaceutical company specializing in oxygen therapeutics, today announces the publication of preclinical data demonstrating that Hemopure…